University of Oxford (UOXF)

University of Oxford
University of Oxford has been one of the world’s most influential universities for eight centuries, renowned for both its research and teaching. Oxford has more world-leading academics (rated 4* in the UK Government’s 2014 Research Effectiveness Framework Exercise) and a higher research income (£600 million in 2014) than any other UK university. Of the University’s four academic divisions, Medical Sciences accounts for over 60% of external research income. The Division is internationally recognised for its research and is one of the largest biomedical research centres in Europe, with over 2,500 researchers and 2,800 students across 5 non-clinical and 12 clinical departments, which includes the Nuffield Department of Clinical Neurosciences (NDCN).The Centre for Prevention of Stroke and Dementia (CPSD) is one of the five divisions of NDCN. Its aims are to do research that increases understanding of the causes of cerebrovascular disease and improve the prevention of stroke and vascular dementia in routine clinical practice. The centre was founded as the Stroke Prevention Research Unit (SPRU) in 2000 by Professor Peter Rothwell with initial funding from the MRC and the Stroke Association. Now comprising about 40 researchers and support staff, the centre is regarded as one of the most productive stroke research groups in the world.Our main areas of current research include:

  • Pathology, prognosis and treatment of carotid stenosis
  • Understanding of the link between blood pressure and risks of stroke and dementia
  • Improve secondary prevention of stroke after a TIA (transient ischaemic attack) or minor stroke
  • Improving phenotyping and prevention of stroke by more effective brain and vascular imaging
  • Biomarkers and genetics of ischaemic stroke and vascular cognitive impairment
  • Reliable determination of the effects of treatments, including randomized trials, systematic reviews, developing methods to better target treatments at individuals and alternatives to randomised trials.
  
Our research has led to major changes in clinical practice and clinical guidelines on multiple aspects of primary and secondary prevention of stroke, including:

  1. Prevention of stroke in patients with recently symptomatic carotid stenosis
  2. Urgency of assessment and investigation of patients with TIA and minor stroke
  3. Effective secondary prevention after TIA and minor stroke
  4. Diagnosis and treatment of hypertension in prevention of stroke

Roles and tasks of UOXF in SVDs@target

CPSD has a particular interest in hypertension and stroke and the effect of BPv on cerebral perfusion and end-organ damage. CPSD will lead the clinical section of WP1 and will contribute to WP 5 (Interventions).

 

 

Key staff

Prof. Peter Rothwell


Action Research Professor of Neurology (Oxford), endowed chair;
Director of the Stroke Prevention Research Unit (Oxford);
Director of the Stroke and Dementia Theme of the Oxford Biomedical Research Centre;
Executive committee member of the European Stroke Organisation (ESO);

 

Major field of research: stroke and dementia; hypertension; specific expertise in: epidemiology, clinical research, BP measurement and monitoring.

 

Prof. Rothwell has extensive experience in international and national collaborative projects and has been the lead investigator in multiple large-scale clinical studies. He also has long-standing expertise in randomised controlled trials in prevention of stroke.

 

SVD@target team at UVM

Dr. Shane Lyons

Research Fellow

 

Dr. Alastair Webb

Research Fellow

Clinician Scientist with experience of analysis and interpretation of BP monitoring data and vascular physiology studies.

 

Search
Home
Menu
Top

Tweets by SVDS@target

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!